{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:29:20Z","timestamp":1787758160820,"version":"build-2784847793"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>This retrospective chart review of netarsudil (Rhopressa) characterizes intra-ocular pressure (IOP) reduction, drug tolerance, drug cost, and compliance in a tertiary university Midwest clinic in a variety of glaucoma diagnoses on patients prescribed netarsudil 01\/2017 to 5\/2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patient demographics, primary diagnosis, indication for medication, prescription date, prescription fill status, duration of use, discontinuation reason, and number of IOP-lowering medications were noted. Confounding medication changes were excluded from IOP analysis. The IOP difference between the first visit after starting netarsudil and the baseline (mean before starting netarsudil on the stable medication regimen) was calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 133 patients were prescribed netarsudil (age 69 \u00b1 20 years, 59% females, 79% white, 86% primary glaucoma) as adjunct glaucoma medication (mean medications 3.2 \u00b1 0.9). Indications were lowering IOP (mean baseline IOP 20.0 \u00b1 6 mmHg) and drug regimen simplification. Prescription was not filled by 22\/133 subjects because of the cost (68%) and the need for surgery (23%). No demographic factors were associated with prescription fill status. A total of 101 eyes of 76 patients were used for IOP analysis. The mean change in IOP was \u20130.8 \u00b1 6.4 mmHg, (IOP decrease in 67%, increase or no change in 33% eyes). Netarsudil was discontinued in 52% (50\/96) patients; the reasons include surgery for IOP control (42%), allergies (30%), cost (14%), and paradoxical rise in IOP (12%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Netarsudil was used as adjunct third or fourth line medication at a glaucoma practice in Midwestern USA. 17% of prescriptions went unfilled; netarsudil was discontinued in 52% of patients. IOP response was variable in this population with severe complex glaucoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_2947_21","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T11:45:11Z","timestamp":1659613511000},"page":"2906-2910","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Pragmatic adjunctive usage of netarsudil: A retrospective chart review from a tertiary care center"],"prefix":"10.4103","volume":"70","author":[{"given":"Nate S","family":"Goergen","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha, NE, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghal","family":"Gagrani","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Gulati","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha, NE, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepta","family":"Ghate","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Emory School of Medicine, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"key":"B1-20240828","first-page":"887","article-title":"Glaucoma is second leading cause of blindness globally","volume":"82","author":"Kingman","year":"2004","journal-title":"Bull World Health Organ"},{"key":"B2-20240828","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040:A systematic review and meta-analysis","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology"},{"key":"B3-20240828","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.ophtha.2007.03.016","article-title":"Predictors of long-term progression in the early manifest glaucoma trial","volume":"114","author":"Leske","year":"2007","journal-title":"Ophthalmology"},{"key":"B4-20240828","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The ocular hypertension treatment study:A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"B5-20240828","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0161-6420(01)00873-9","article-title":"Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery","volume":"108","author":"Lichter","year":"2001","journal-title":"Ophthalmology"},{"key":"B6-20240828","first-page":"1403","article-title":"2. Results of argon laser trabeculoplasty versus topical medicines. The Glaucoma Laser Trial Research Group","volume":"97","year":"1990","journal-title":"Ophthalmology"},{"key":"B8-20240828","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/ICU.0000000000000346","article-title":"New classes of glaucoma medications","volume":"28","author":"Schehlein","year":"2017","journal-title":"Curr Opin Ophthalmol"},{"key":"B9-20240828","first-page":"205","article-title":"Pharmaceutical approval update","volume":"43","author":"Choy","year":"2018","journal-title":"PT"},{"key":"B10-20240828","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1089\/jop.2017.0138","article-title":"The effects of netarsudil ophthalmic solution on aqueous humor dynamics in a randomized study in humans","volume":"34","author":"Kazemi","year":"2018","journal-title":"J Ocul Pharmacol Ther"},{"key":"B11-20240828","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.2147\/OPTH.S154001","article-title":"Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma:Evidence to date","volume":"12","author":"Dasso","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"B12-20240828","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/jps.20285","article-title":"Contribution of ROCK in contraction of trabecular meshwork:Proposed mechanism for regulating aqueous outflow in monkey and human eyes","volume":"94","author":"Nakajima","year":"2005","journal-title":"J Pharm Sci"},{"key":"B13-20240828","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/jop.2014.0146","article-title":"Effect of AR-13324 on episcleral venous pressure in Dutch belted rabbits","volume":"31","author":"Kiel","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"key":"B14-20240828","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/IJG.0b013e3182952213","article-title":"Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes","volume":"24","author":"Rf","year":"2015","journal-title":"J Glaucoma"},{"key":"B15-20240828","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","article-title":"Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure:Rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2)","volume":"186","author":"Serle","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"B16-20240828","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/IJG.0000000000001634","article-title":"Pooled efficacy and safety profile of netarsudil ophthalmic solution 0.02% in patients with open-angle glaucoma or ocular hypertension","volume":"29","author":"Singh","year":"2020","journal-title":"J Glaucoma"},{"key":"B17-20240828","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ajo.2019.03.002","article-title":"Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure:The randomized phase 3 ROCKET-4 study","volume":"204","author":"Khouri","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"B18-20240828","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ophtha.2014.08.022","article-title":"Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure","volume":"122","author":"Bacharach","year":"2015","journal-title":"Ophthalmology"},{"key":"B19-20240828","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s12325-020-01277-2","article-title":"Fixed-dose combination of netarsudil and latanoprost in ocular hypertension and open-angle glaucoma:Pooled efficacy\/safety analysis of phase 3 MERCURY-1 and -2","volume":"37","author":"Asrani","year":"2020","journal-title":"Adv Ther"},{"key":"B20-20240828","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrd3501","article-title":"Bridging the efficacy\u2013effectiveness gap:A regulator's perspective on addressing variability of drug response","volume":"10","author":"Eichler","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"B21-20240828","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamaophthalmol.2013.7677","article-title":"Effectiveness of intraocular pressure\u2013lowering medication determined by washout","volume":"132","author":"Jampel","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"B22-20240828","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/17469899.2019.1635456","article-title":"Medication adherence in patients with ocular hypertension or glaucoma","volume":"14","author":"Robin","year":"2019","journal-title":"Expert Rev Ophthalmol"},{"key":"B23-20240828","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0002-9394(02)01922-0","article-title":"A paradoxical ocular effect of brimonidine","volume":"135","author":"Mushtaq","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"B24-20240828","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ogla.2020.10.005","article-title":"Early experience with netarsudil in pediatric patients:A retrospective case series","volume":"4","author":"Rapuano","year":"2021","journal-title":"Ophthalmol Glaucoma"},{"key":"B25-20240828","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ogla.2020.01.005","article-title":"Netarsudil's effect in eyes with a history of selective laser trabeculoplasty","volume":"3","author":"Lin","year":"2020","journal-title":"Ophthalmol Glaucoma"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_2947_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:08:25Z","timestamp":1787756905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_2947_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_2947_21","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,29]]},"assertion":[{"value":"2021-12-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}